Micromet Appoints Ulrich Grau, Ph.D. Executive Vice President and Chief Operating Officer
Complete the form below to unlock access to ALL audio articles.
"We are delighted to welcome Uli to Micromet," said Christian Itin, Ph.D., Micromet's President and CEO. "Uli's global operations management experience and demonstrated track record of successful late-stage product development will be extremely valuable as we look to deliver on substantial clinical development and commercial goals for blinatumomab."
Dr Grau most recently served as President and CEO of Lux Biosciences, Inc, a clinical stage private ophthalmic company that he co-founded. From 2002 to 2005, he served as Enzon’s Chief Scientific Officer and head of R&D. During his tenure at Enzon, he upgraded the company's R&D capabilities and built a portfolio of product candidates based on Enzon’s proprietary technologies and partnered programs. Prior to joining Enzon, Dr. Grau served as President of Research and Development and was a member of the Executive Board at BASF Pharma/Knoll where he directed a global R&D organization and significantly advanced and expanded the Company’s product portfolio, which included development of adalimumab (Humira®). Earlier in his career, Dr. Grau served as Senior Vice President and R&D integration officer of Aventis Pharma, and as Senior Vice President Global Product Realization at Hoechst Marion Roussel where he directed the company’s global late-stage product development activities.
Dr Grau received his Ph.D. in chemistry and biochemistry from the University of Stuttgart and spent three years as a post-doctoral fellow at Purdue University in the field of protein crystallography.
